关键词: 钠葡萄糖协同转运蛋白2；SGLT2抑制剂；达格列净；卡格列净；恩格列净；糖尿病, 2型；慢性肾脏病；心脑血管疾病

Abstract: Type 2 diabetes mellitus （T2DM） is an independent risk factor for cardiovascular events，with 80% of patients dying of cardiovascular diseases.Long-term use of traditional hypoglycemic drugs can cause adverse reactions such as weight gain，increased blood pressure，and frequent hypoglycemia，which can increase the risk of cardiovascular events.Recent studies have shown that a new class of glucose-lowering drugs，sodium glucose transporter 2 （SGLT2） inhibitors，can simultaneously reduce blood glucose，body weight，and blood pressure and improve cardiovascular outcomes in patients with T2DM.However，most of these data came from studies with people with normal kidney function.In the real world，20% to 40% of patients with T2DM also have chronic kidney disease（CKD），but there are relatively few studies on SGLT2 inhibitors in these patients.This article reviews the evidence from recent clinical studies，including the effect of SGLT2 inhibitors on cardiovascular and cerebrovascular risk factors such as elevated plasma fasting blood glucose，blood pressure，body weight and blood lipid，as well as on cardiovascular and cerebrovascular outcomes in patients with T2DM and CKD，with a conclusion that SGLT2 inhibitors could effectively lower blood glucose，blood pressure and body weight as well as improve cardio-cerebrovascular outcomes，but different SGLT2 inhibitors have different cardio-cerebrovascular protective effects.

Key words: Sodium glucose transporter 2；SGLT2 inhibitor；Dapagliflozin；Canagliflozin；Empagliflozin；Diabetes mellitus, type 2；Chronic kidney disease；Cardiovascular diseases